Chairman, Medical Oncology and Hematology, UF Health Cancer Center at Orlando Health
Oncology
Dr. Julio J. Hajdenberg, MD
|
|
Give Review
Julio Hajdenberg practices Oncology. He went to medical school at Harvard Medical School. Harvard Medical School is one of the top medical schools in the US. Harvard Medical School has a rank of 1 in research and a 12 in primary care He over the years received 8 awards: "Best doctor", "Fellow (FACP)", "Fellow", "Awardee - Clinical Trials Design Workshop", "Awardee - Molecular Biology/Oncology Workshop", "Clinical Trials Workshop Awardee", "Molecular Biology Workshop Awardee" and "Health Care Provider of the Year 2013". Julio Hajdenberg is a published doctor. He published 19 publications, including: 'Sacituzumab Govitecan, a Novel Antibody-Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma.' Julio Hajdenberg is registered with Medicare and accepts Medicare payments.
Publications
- Sacituzumab Govitecan, a Novel Antibody-Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma.
- Locally advanced paraganglioma of the urinary Bladder: a case report.
- A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients With relapsed or refractory germ cell tumors.
- Pheochromocytoma of the urinary Bladder: a systematic review of the contemporary literature.
- An international expanded-access programme of everolimus: addressing safety and efficacy in patients With metastatic renal cell carcinoma who progress after initial va...
- Adjuvant trastuzumab in HER2-positive breast Cancer.
- ACP Journal Club. Review: Self-testing or self-management of oral antiCoagulation reduces thromboembolic events and mortality more than usual care.
- Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal Cell carcinoma sorafenib expanded access program.
- Phase 3 trial of everolimus for metastatic renal Cell carcinoma : final results and analysis of prognostic factors.
- Safety and efficacy results of the advanced renal Cell carcinoma sorafenib expanded access program in North America.
- ACP Journal Club. Continuous androgen-deprivation therapy increased risk for diabetes and fragility fractures in older men with prostate Cancer.
- ACP Journal Club. Adding radiotherapy to endocrine therapy improved survival in locally advanced prostate Cancer.
- Efficacy of everolimus in advanced renal Cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
- Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
- Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
- Template bleeding time and PFA-100 have low sensitivity to screen patients With hereditary mucocutaneous hemorrhages: comparative study of 148 patients--a rebuttal.
- Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting With palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results o...
- Factor VIII antibodies developing after a spider bite.
Schools
Universidad De Buenos Aires Facultad De Ciencias Medicas
UMDNJ Cooper Hospital University Med Center
Harvard Medical School Beth Israel Deaconess Medical Center
Procedures Preformed
- Bone Marrow Aspiration
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- View All
Doctors Specialties
- Adult Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Best doctor
- Fellow (FACP)
- Fellow
- Awardee - Clinical Trials Design Workshop
- Awardee - Molecular Biology/Oncology Workshop
- Clinical Trials Workshop Awardee
- Molecular Biology Workshop Awardee
- Health Care Provider of the Year 2013
Education
-
Beth Israel Deaconess Medical Center -
Harvard Medical School -
Cooper University Hospital -
University of Buenos Aires
Hospital
-
Orlando Regional Medical Center
Drug Facts
| NPI NUMBER | 1255315958 | |
| NPPES Provider LastName | HAJDENBERG | |
| NPPES Provider FirstName | JULIO | |
| NPPES Provider ZIPCode | 328062134 | |
| NPPES Provider State | FL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 711.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 26.0 | |
| Percent Opioid Claims | 3.66 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1255315958 |
| Last Name Of The Provider | HAJDENBERG |
| First Name Of The Provider | JULIO |
| View All |
Similar Doctors
|
Dr. Gopal R. Kunta, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nikita C. Shah, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Omar R. Kayaleh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer E. Tseng, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sreeram Maddipatla, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sajeve S. Thomas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Faseeh U. Khaja, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ralph Gousse, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Larisa Greenberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. B J. Alexander, MD |